Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Biogen Idec | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Biogen Idec

MS drug TECFIDERA drives growth in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Biogen Idec
 
2Q Revenues: $2.4 billion (+40%)

2Q Earnings: $723.1 million (+47%)

YTD Revenues: $4.6 billion (+45%)

YTD Earnings: $1.2 billion (+31%)

Comments: Growth in the quarter was driven by continued uptake of MS drug TECFIDERA, with revenues of $700 million, consisting of $585 million in U.S. sales and $115 million in sales outside the U.S. TYSABRI revenues were $533 million, up 38%. Avonex revenues were flat at $774 million in the quarter. Net revenues relating to RITUXAN and GAZYVA from the company’s unconsolidated joint business arrangement with Roche’s Genentech, were $303 million, up from $289 million in 2Q13.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters